Comparison

Anti-Human CD19 - DyLight® 488

Item no. LEIN-C1970-100ug
Manufacturer Leinco Technologies
Amount 100 ug
Quantity options 100 ug 200 ug 50 ug
Category
Type Antibody Primary
Applications FC
Clone SJ25-C1
Specific against Human (Homo sapiens)
Host Mouse
NCBI 930
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Shipping condition Cool pack
Available
Manufacturer - Category
Primary Monoclonal Antibodies>SurfaceTag Human CD Markers
Manufacturer - Targets
CD19
Country of Origin
USA
Shipping Temperature
Next Day 2-8°C
Storage Conditions
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Product Description
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling.
Background
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling.
PubMed
CD19
Excitation Laser
Blue Laser (493 nm)
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Manufacturer - Research Area
Costimulatory Molecules, Immunology
Manufacturer - Specificity
Clone SJ25-C1 recognizes an epitope on human CD19.
RRID
AB_2829055
Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Antigen Distribution
CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19.
Immunogen
NALM1 + NALM16 cells
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close